Hematological Malignancies

UK RAPID; EORTC/LYSA H10 RT or no RT in PET-negative early stage HL • Central PET review necessary • More events in PET- patients with chemo only • Similar findings but opposite conclusions (8 vs 20 and 8 vs 25 events) between RAPID 1 and H10 2 • Rapid failed to demonstrate non-inferiority (HR 1.57; p=0.27) with PFS differences of up to 8.8% (ITT) and 11.0% (per protocol) • No difference between PET+ and PET- patients –questionable role of PET in this setting! • Deleting RT in PET- early stage HL still experimental

1 Radfort et al NEJM 2015 2 Raemakers et al JCO 2015